Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/26/2026

1. INTU
2. DKS
3. ZM
4. META
5. SMTC
6. SPY
7. NCNO
8. JAZZ
9. NVDA
10. BOX

Go back to Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight

2017 Seen as a Challenge for Teva (TEVA), But Sticking with 'Buy' - Maxim

November 16, 2016 8:25 AM EST

Maxim Group analyst Gabrielle Zhou lowered her price target on Teva Pharma (NYSE: TEVA) to $52.00 (from $72.00) but maintained a Buy rating following results. The firm sees 2017 as a challenge.

Zhou commented:

Teva reported 3Q16 with total revenues of $5.6B, with $2.9B in generic product revenues, including $887M from the Actavis generic business (transaction completed on Aug. 2, 2016). Total generic revenues increased 26% sequentially, compared to $2.3B in 2Q16. Specialty revenues were $2B, down 10%... More

BTIG Downgrades Teva Pharma (TEVA) to Neutral

November 16, 2016 7:33 AM EST

BTIG downgraded Teva Pharma (NYSE: TEVA) from Buy to Neutral and removed its price target. Analyst Timothy Chiang noted Copaxone risk.

"We downgrade TEVA shares to Neutral based on three key factors: 1) poor visibility on near term revenue growth drivers for the generic / branded... More

Jefferies Downgrades Teva Pharma (TEVA) to Hold; Too Many Headwinds

November 16, 2016 6:32 AM EST

Jefferies downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $40.00 (from $69.00), saying there are too many headwinds.

Analyst David Steinberg commented, "Our view has changed. We now think there is little over the next year... More